[go: up one dir, main page]

PL3846810T3 - Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie - Google Patents

Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie

Info

Publication number
PL3846810T3
PL3846810T3 PL19773583.0T PL19773583T PL3846810T3 PL 3846810 T3 PL3846810 T3 PL 3846810T3 PL 19773583 T PL19773583 T PL 19773583T PL 3846810 T3 PL3846810 T3 PL 3846810T3
Authority
PL
Poland
Prior art keywords
lasmiditan
migraine prevention
chronic nightly
dosing
nightly dosing
Prior art date
Application number
PL19773583.0T
Other languages
English (en)
Inventor
Robert Russell CONLEY
Gudarz Davar
Kirk Willis Johnson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68051892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3846810(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3846810T3 publication Critical patent/PL3846810T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
PL19773583.0T 2018-09-04 2019-09-03 Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie PL3846810T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (1)

Publication Number Publication Date
PL3846810T3 true PL3846810T3 (pl) 2024-03-18

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19773583.0T PL3846810T3 (pl) 2018-09-04 2019-09-03 Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie

Country Status (37)

Country Link
US (1) US12138254B2 (pl)
EP (2) EP3846810B1 (pl)
JP (2) JP7321256B2 (pl)
KR (1) KR102649644B1 (pl)
CN (1) CN112638383A (pl)
AU (3) AU2019336667B2 (pl)
BR (1) BR112021002945A2 (pl)
CA (1) CA3111205A1 (pl)
CL (1) CL2021000529A1 (pl)
CO (1) CO2021002766A2 (pl)
CR (1) CR20210126A (pl)
DK (1) DK3846810T3 (pl)
DO (1) DOP2021000039A (pl)
EA (1) EA202190440A1 (pl)
EC (1) ECSP21015491A (pl)
ES (1) ES2967665T3 (pl)
FI (1) FI3846810T3 (pl)
HR (1) HRP20231587T1 (pl)
HU (1) HUE064519T2 (pl)
IL (1) IL281208B2 (pl)
JO (1) JOP20210033A1 (pl)
LT (1) LT3846810T (pl)
MA (1) MA53551B1 (pl)
MD (1) MD3846810T2 (pl)
MX (1) MX2021002474A (pl)
MY (1) MY199662A (pl)
PE (1) PE20211599A1 (pl)
PH (1) PH12021550448A1 (pl)
PL (1) PL3846810T3 (pl)
PT (1) PT3846810T (pl)
RS (1) RS64857B1 (pl)
SG (1) SG11202101530PA (pl)
SI (1) SI3846810T1 (pl)
TW (1) TWI826514B (pl)
UA (1) UA129587C2 (pl)
WO (1) WO2020051137A1 (pl)
ZA (1) ZA202100666B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR20230107902A (ko) 2014-02-05 2023-07-18 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2021319090A1 (en) * 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
US12350259B2 (en) 2021-09-27 2025-07-08 Allergan Pharmaceuticals International Limited Methods of treating migraine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
AU7261196A (en) 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
HUP9902901A3 (en) 1996-08-28 2002-01-28 Lilly Co Eli Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta[b]benzofurans
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
CN1149195C (zh) 1999-02-10 2004-05-12 伊莱利利公司 5－ht1f激动剂
ID30056A (id) 1999-02-26 2001-11-01 Lilly Co Eli Agonis-agonis 5-htif
KR100849981B1 (ko) 2000-07-13 2008-08-01 메르크 파텐트 게엠베하 키랄 화합물 ｉ
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US6900210B2 (en) 2002-11-22 2005-05-31 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
EP1819330A1 (en) 2004-12-01 2007-08-22 Devgen N.V. 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
CN102753171A (zh) * 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
KR20210102497A (ko) 2016-12-06 2021-08-19 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
EP4279132A2 (en) 2023-11-22
KR20210039419A (ko) 2021-04-09
EP3846810B1 (en) 2023-10-18
IL281208B2 (en) 2025-02-01
CL2021000529A1 (es) 2021-08-13
IL281208B1 (en) 2024-10-01
MY199662A (en) 2023-11-15
US12138254B2 (en) 2024-11-12
CR20210126A (es) 2021-04-22
FI3846810T3 (fi) 2023-12-15
AU2019336667B2 (en) 2022-09-29
TW202033197A (zh) 2020-09-16
HUE064519T2 (hu) 2024-03-28
SG11202101530PA (en) 2021-03-30
JP7543497B2 (ja) 2024-09-02
EP3846810A1 (en) 2021-07-14
MA53551B1 (fr) 2023-11-30
AU2022291568A1 (en) 2023-02-02
ES2967665T3 (es) 2024-05-03
WO2020051137A1 (en) 2020-03-12
IL281208A (en) 2021-04-29
CA3111205A1 (en) 2020-03-12
LT3846810T (lt) 2024-01-10
SI3846810T1 (sl) 2023-12-29
JP7321256B2 (ja) 2023-08-04
ECSP21015491A (es) 2021-04-29
HRP20231587T1 (hr) 2024-03-15
KR102649644B1 (ko) 2024-03-21
AU2019336667A1 (en) 2021-03-11
MX2021002474A (es) 2021-08-24
PH12021550448A1 (en) 2021-09-27
RS64857B1 (sr) 2023-12-29
PE20211599A1 (es) 2021-08-18
EP4279132A3 (en) 2024-03-06
AU2025201479A1 (en) 2025-03-20
PT3846810T (pt) 2023-12-14
CN112638383A (zh) 2021-04-09
JP2021535913A (ja) 2021-12-23
ZA202100666B (en) 2024-09-25
CO2021002766A2 (es) 2021-03-19
MA53551A (fr) 2022-01-12
JP2023156344A (ja) 2023-10-24
BR112021002945A2 (pt) 2021-05-11
UA129587C2 (uk) 2025-06-11
NZ774400A (en) 2024-03-22
DK3846810T3 (da) 2023-12-04
TWI826514B (zh) 2023-12-21
EA202190440A1 (ru) 2021-06-24
JOP20210033A1 (ar) 2021-02-25
MD3846810T2 (ro) 2024-04-30
US20210338655A1 (en) 2021-11-04
DOP2021000039A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
IL281208A (en) Chronic nocturnal dosing of lasmiditan for migraine prevention
IL323063A (en) Combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for cancer treatment
SG11202005583QA (en) Ex situ coating of chamber components for semiconductor processing
IL281939A (en) VAP-1 inhibitors
SI3700902T1 (sl) Inhibitorji trpc6
IL275457A (en) Spiro exo-aza inhibitors of the MENIN-MLL interaction
IL265342A (en) Use of pridofidine for the treatment of Rett syndrome
IL272061A (en) Preparations for the treatment of stress-related disorders
IL281815A (en) VAP-1 inhibitors
IL253854A0 (en) A polymorph of mebendazole for the treatment and prevention of tumors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
LT3573620T (lt) Kompozicijos, skirtos hipertenzijos gydymui
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL283627A (en) Improved transport of large materials
GB2577661B (en) Determination of lithography effective dose uniformity
SG11201607473PA (en) Composition for maintaining efficacy of filler
IL262111B1 (en) Monovalent inhibitors of hutnfr1 interaction
PT3250203T (pt) Composição para utilização crónica como composto para ganho de peso
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
IL263336A (en) Compounds for the treatment of symphysiolysis
IL274552A (en) Treatment of side effects of botulinum treatments
IL231047A0 (en) Inhibitors of leukotriene-mediated activity to prevent or alleviate side effects of chemotherapy
SG11202003590YA (en) Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones
GB201602249D0 (en) Dosage regimen for the treatment of acute exacerbations of inflammatory conditions